RenovoRx, Inc.
RNXT Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 26, 2026
$1.31
KIRA · Stoqly’s AI analyst, in plain words
- RenovoRx, Inc. had $1.1M of revenue in fiscal 2025, up 2,511.6% on the year before.
- Its operating margin was −1,114.0%, up 24,397.6 pts: of every 100 in sales, about −1,114 is left after running the business.
- RenovoRx, Inc. lost $11.2M in fiscal 2025.
- Free cash flow was −$11.0M in fiscal 2025, −977.3% of revenue.
Market cap
$62.0M
P/E
—
Revenue
$1.1M
Net income
−$11.2M
Free cash flow
−$11.0M
Operating margin
−1,114.0%
RenovoRx, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+2,511.6%
Yes. Sales grew 2,511.6% last year.
Does it make a profit?
−994.5%
No. It lost money last year.
Does profit turn into cash?
−977.3%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What RenovoRx, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 30, 2026
- Legal name
- RenovoRx, Inc.
- CIK
- 0001574094
RenovoRx, Inc. · RNXT
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | −$0.8M | — | — | $0.0M | $1.1M |
| Revenue growth | — | — | — | — | 2,511.6% |
| Net interest income | −$0.8M | — | — | — | — |
| Gross margin | — | — | — | 100.0% | 70.9% |
| Operating margin | 680.0% | — | — | −25,511.6% | −1,114.0% |
| Net income | −$6.3M | −$9.9M | −$10.2M | −$8.8M | −$11.2M |
| Net margin | 758.3% | — | — | −20,497.7% | −994.5% |
| Diluted EPS | −$1.21 | −$1.09 | −$0.99 | −$0.40 | −$0.32 |
| Cash | |||||
| Cash from operations | −$5.9M | −$8.8M | −$10.3M | −$9.1M | −$11.0M |
| Capital expenditure | — | — | — | $0.0M | $0.0M |
| Free cash flow | — | — | — | −$9.1M | −$11.0M |
| FCF margin | — | — | — | −21,248.8% | −977.3% |
| Share count change | 135.6% | 73.5% | 13.7% | 116.4% | 58.6% |
| Debt and strength | |||||
| Cash and short-term investments | $15.2M | $6.4M | $1.2M | $7.2M | $7.0M |
| Shareholders' equity | $15.3M | $6.2M | $3.0M | $4.5M | $5.4M |
| Current ratio | 17.4x | 6.6x | 1.2x | 4.1x | 4.0x |
| Returns and quality | |||||
| Return on equity | −1,825.1% | −91.9% | −223.3% | −235.7% | −225.6% |
| Return on tangible equity | −41.2% | −160.5% | −341.1% | −196.8% | −206.0% |
| Piotroski F-score | 4 | — | — | — | 2 |
| Altman Z'' | 16.8 | −11.8 | −142.3 | −23.2 | −28.2 |
Insiders bought, 12 months
$0.1M
3 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
RenovoRx, Inc. · RNXT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.31 a share, the company is worth $62.0M.
Source: SEC EDGAR XBRL filings (CIK 0001574094). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.